Minimally Invasive TAVR Procedure Now FDA Approved for More Patients

Most patients with heart valve disease may be candidates for the transcatheter aortic valve replacement (TAVR) procedure as an alternative to open-heart surgery. In August 2019, the Food and Drug Administration (FDA) expanded the eligibility criteria to patients who are at low risk for major complications associated with open-heart surgery. Previously the FDA approved TAVR devices only for patients evaluated as medium or high risk.

Since the UA Sarver Heart Center’s Structural Heart Disease team started offering the TAVR procedure in 2012, about 417 patients have benefited from this advance that requires a small incision in the groin to implant a new valve via catheter. Most patients return home the following day and recover more quickly than patients who undergo open-heart surgery.

“The technology for transcatheter valve replacement continues to advance, allowing more and more valves to be replaced less invasively,” said Kapil Lotun, MD, director of the Structural Heart Disease Program at UA Sarver Heart Center.

Devan Lodge, RN, MSc, CCRN and Erin Scala, RN, BSN

Meet Our Structural Heart Team and some of the patients who are once again living their lives fully after getting their heart valves replaced with the latest minimally invasive procedures.

For more information or to refer a patient, contact: 
Phone: (520) 694-8578 • Fax: (520) 694-1007 • BUMCTStructuralHeart@bannerhealth.com

For more health information, please visit our  Heart Health page.

For physician appointment information, please call 520-MyHeart (694-3278).

If you appreciate the content found on our website, please consider a donation to the Sarver Heart Center.